Literature DB >> 6488690

Abnormal serum protein binding of acidic drugs in diabetes mellitus.

F Ruiz-Cabello, S Erill.   

Abstract

Nonenzymatic glycosylation of proteins is common in diabetes mellitus and glycosylation of serum albumin in this condition has been described. To evaluate whether glycosylation of albumin affects acidic drug binding, sulfisoxazole and diazepam binding was examined in samples of normal serum incubated with glucose and in samples of serum from 42 patients with diabetes mellitus. Incubation of normal serum with 20mM glucose for several days resulted in progressive glycosylation of proteins, with decreased binding of sulfisoxazole (100 micrograms/ml) but not of diazepam (3 micrograms/ml). Free fractions of sulfisoxazole and diazepam were higher in serum from patients with diabetes. The percentage of free sulfisoxazole in serum from 10 normal subjects was 5.1% +/- 0.2%, whereas it was 16.0% +/- 1.3% in serum from 42 patients with diabetes with varying degrees of carbohydrate control. The percentage of free diazepam in plasma was 2.6% +/- 0.1% in the normal group and 3.6% +/- 0.4% in patients with diabetes. Decreased serum albumin levels, increased levels of free fatty acids, and glycosylation of plasma proteins seem to play a role in the defective acidic drug binding in diabetes. Elevated free fatty acid levels explain the abnormal binding of diazepam and the increased free fraction of sulfisoxazole is directly related to glycosylation of plasma proteins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488690     DOI: 10.1038/clpt.1984.241

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 3.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

4.  Pharmacokinetics of zopolrestat, a carboxylic acid aldose reductase inhibitor, in normal and diabetic rats.

Authors:  P B Inskeep; A E Reed; R A Ronfeld
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

5.  Proceedings of the British Pharmacological Society, Clinical Pharmacology Section. Ireland, 6-8 July, 1988. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

7.  Crystal structure of equine serum albumin in complex with cetirizine reveals a novel drug binding site.

Authors:  Katarzyna B Handing; Ivan G Shabalin; Karol Szlachta; Karolina A Majorek; Wladek Minor
Journal:  Mol Immunol       Date:  2016-02-17       Impact factor: 4.407

Review 8.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Protein binding of digitoxin, valproate and phenytoin in sera from diabetics.

Authors:  J Doucet; J Fresel; G Hue; N Moore
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Plasma protein binding of lidocaine and warfarin in insulin-dependent and non-insulin-dependent diabetes mellitus.

Authors:  S O'Byrne; M G Barry; W C Collins; P O'Connor; M J Cullen; J Feely
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.